Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,111 result(s) found for: Brain function. Displaying page 8 of 56.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2012-002714-40 Sponsor Protocol Number: RPC01-201 Start Date*: 2013-05-09
    Sponsor Name:Receptos, Inc.
    Full Title: A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY...
    Medical condition: RELAPSING MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) HU (Completed) BG (Completed) GR (Completed) GB (Completed) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003452-21 Sponsor Protocol Number: BRF117277 Start Date*: 2014-01-27
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain.
    Medical condition: Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003089-14 Sponsor Protocol Number: CCTU0218 Start Date*: 2019-12-03
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Azathioprine Immunosuppression and Disease Modification in Parkinson’s Disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023023-19 Sponsor Protocol Number: CFTY720DIT01 Start Date*: 2010-12-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002500-91 Sponsor Protocol Number: RPC01-3001 Start Date*: 2015-10-12
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006006-22 Sponsor Protocol Number: ICH01 Start Date*: 2009-01-14
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust [...]
    1. Newcastle upon Tyne Hospitals NHS Trust
    2. Johns Hopkins University
    Full Title: Minimally Invasive Surgery plus rt-PA for ICH Evacuation
    Medical condition: intracerebral hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10062025 Intracerebral haematoma evacuation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022838-85 Sponsor Protocol Number: MEK114267 Start Date*: 2010-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: MEK114267, A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma
    Medical condition: Advanced or metastatic BRAF V600E/K mutation-positive melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) CZ (Completed) GR (Completed) NO (Completed) GB (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002976-28 Sponsor Protocol Number: CCNP520A2202J Start Date*: 2017-05-16
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease ...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FI (Prematurely Ended) IS (Completed) PT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002530-20 Sponsor Protocol Number: GEM-1802 Start Date*: 2019-03-12
    Sponsor Name:Grupo Español Multidisciplinar de Melanoma
    Full Title: Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain.
    Medical condition: BRAF mutant melanoma metastatic to the brain
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-001617-32 Sponsor Protocol Number: MINOR Start Date*: 2013-12-05
    Sponsor Name:AUSL di Piacenza
    Full Title: Thrombolysis in Minor Stroke
    Medical condition: The condition to be treated is the stroke of “minor” grade (National Institutes of Health Stroke Scale (NIHSS) score < 5).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004494-23 Sponsor Protocol Number: MAG104615 Start Date*: 2013-03-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients
    Medical condition: Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000698-38 Sponsor Protocol Number: MD1003CT2014-01AMN Start Date*: 2014-08-13
    Sponsor Name:MEDDAY SAS
    Full Title: MD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024119-15 Sponsor Protocol Number: rs4680-tolcapona Start Date*: 2014-04-10
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680
    Medical condition: Esquizofrenia crónica controlada. (10 pacientes con el genotipo val/val y 10 pacientes con el genotipo met/met)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10009134 Chronic schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2007-001283-73 Sponsor Protocol Number: 109493 Start Date*: 2007-08-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable ...
    Medical condition: Adjuvant therapy in patients with MAGE-A3-positive Non-Small Cell Lung Cancer (NSCLC) and who have had complete surgical resection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) FR (Completed) SE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) AT (Completed) NL (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010004-28 Sponsor Protocol Number: ACNS0331 Start Date*: 2010-04-14
    Sponsor Name:COG
    Full Title: ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblas...
    Medical condition: Medulloblastoom standard risk
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027107 Medulloblastoma LLT
    12.0 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002151-10 Sponsor Protocol Number: NEUROPROTECTpost-CA Start Date*: 2015-08-07
    Sponsor Name:UZ Leuven
    Full Title: Neuroprotective goal directed hemodynamic optimization in post-cardiac arrest patients: a randomized controlled trial (the NEUROPROTECT post-CA trial)
    Medical condition: post-cardiac arrest patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10047283 Ventricular arrhythmias and cardiac arrest HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004521-17 Sponsor Protocol Number: BIT-001 Start Date*: 2018-02-19
    Sponsor Name:BIT Pharma GmbH
    Full Title: A Phase IIa: single ascending dose safety, tolerability and pharmacokinetic study of NicaPlant® in aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping
    Medical condition: Aneurysmal subarachnoid haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10008111 Cerebral haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000230-53 Sponsor Protocol Number: TMC-CLV-07-02 Start Date*: 2008-05-15
    Sponsor Name:The Medicines Company
    Full Title: The evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment
    Medical condition: Acute hypertension in patients who present with intracerebral hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022754 Intracerebral hemorrhage LLT
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005625-39 Sponsor Protocol Number: I8D-MC-AZET Start Date*: 2016-09-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study)
    Medical condition: Alzheimer’s Disease with Dementia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000572-33 Sponsor Protocol Number: ParvOryx01 Start Date*: 2011-09-02
    Sponsor Name:Oryx GmbH und Co. KG
    Full Title: Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of PArvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 11:51:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA